<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095558</url>
  </required_header>
  <id_info>
    <org_study_id>MST-OC-2021</org_study_id>
    <nct_id>NCT05095558</nct_id>
  </id_info>
  <brief_title>Microtransplantation for Ovarian Cancer</brief_title>
  <official_title>Microtransplantation for Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will apply micro transplantation to the field of recurrent and advanced&#xD;
      ovarian cancer to study the efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eligible patients are assigned to the experimental group (microtransplantation group, MST&#xD;
      group) or the control group (CT) according to the availability of suitable donors. In MST&#xD;
      group, peripheral blood hematopoietic stem cells from HLA mismatched donors mobilized with&#xD;
      granulocyte colony stimulating factor are infused after conventional chemotherapy and/or&#xD;
      radiotherapy ; The CT group only received conventional chemotherapy and/or radiotherapy.&#xD;
      According to the patient's past medical history, current tumor assessment results, and the&#xD;
      latest cancer treatment guidelines, the individualized chemotherapy and / or radiotherapy&#xD;
      plan for the patient is formulated after discussion by more than 3 oncologists. After each&#xD;
      course of treatment, the efficacy and safety are evaluated. For the patients who are&#xD;
      evaluated to be effective or stable (SD) after the first treatment, the second treatment of&#xD;
      the same scheme will be given. Those who reach the disease control level will continue to be&#xD;
      treated for 4 courses, with an interval of 28 days. The patients who failed to achieve the&#xD;
      improvement of SD after two cycles of chemotherapy will be withdrawn from the study. Patients&#xD;
      are allowed to receive any treatment, including symptomatic support treatment, after the end&#xD;
      of treatment or withdrawal from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <description>Treatment related mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time of hematopoietic recovery</measure>
    <time_frame>1 month</time_frame>
    <description>Absolute neutrophil count &gt;500/mcL; Platelets ≥20,000/mcL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>1year</time_frame>
    <description>(markedly effective + effective) / number of patients × 100%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>MST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard chemotherapy with microtransplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard chemotherapy only, without microtransplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>microtransplantation, HLA-mismatched donor peripheral stem cell infusion</intervention_name>
    <description>infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)</description>
    <arm_group_label>MST</arm_group_label>
    <other_name>DSI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are 18-80 years old, female，regardless of race;&#xD;
&#xD;
          -  Advanced / relapsed ovarian cancer confirmed by clinical or histopathological&#xD;
             diagnosis;&#xD;
&#xD;
          -  More than two kinds of tumors are allowed;&#xD;
&#xD;
          -  Karnofsky score ≥ 60, ECoG physical status ≤ 2;&#xD;
&#xD;
          -  Sensitive to chemotherapy or radiotherapy;&#xD;
&#xD;
          -  There are measurable lesions;&#xD;
&#xD;
          -  There are suitable hematopoietic stem cell donors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have no suitable donor or donor refused&#xD;
&#xD;
          -  patient refused to accept donor cells&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>WEIPING LI</last_name>
    <phone>+8615811031508</phone>
    <email>15811031508@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>QIYUN Sun</last_name>
    <phone>+8613651058454</phone>
    <email>13651058454@139.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The third medical center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiping Li</last_name>
      <phone>+8615811031508</phone>
      <email>15811031508@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microtransplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

